<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335965">
  <stage>Registered</stage>
  <submitdate>20/01/2011</submitdate>
  <approvaldate>21/01/2011</approvaldate>
  <actrnumber>ACTRN12611000082909</actrnumber>
  <trial_identification>
    <studytitle>The effect of zoledronate on marrow fat in osteoporotic elderly patients who have suffered a minimal trauma fracture.</studytitle>
    <scientifictitle>A double blind randomised controlled trial assessing the effect of zoledronate on marrow fat in older osteoporotic persons after suffering a minimal trauma fracture</scientifictitle>
    <utrn />
    <trialacronym>FAT</trialacronym>
    <secondaryid>CZOL446HAU30T</secondaryid>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous zoledronic acid (5mg) infused over 30 minutes on one occasion only.</interventions>
    <comparator>Placebo (saline), 100 mL, intravenous, infused over 30 minutes, single dose.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in marrow fat in femur and vertebrae will be quantified using CT and MRI images analysed using an image analysis software (Tomovision).</outcome>
      <timepoint>6 months and 18 months post-infusion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The incidence of fractures will be assessed by requesting the patients to report any minimal trauma fracture. Once the patient has contacted our Research Officer, documentation of the fracture by X-ray (films or report) will be required.</outcome>
      <timepoint>6 months and 18 months post-infusion</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in bone mineral density measure by dual energy X-ray absorptiometry (DXA) scan</outcome>
      <timepoint>18 months post- infusion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1- History of minimal trauma fracture within 90 days before starting the trial
2- Age: Older than 65
3- Female</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Patients taking statins for cholesterol lowering
2) Previous history of diabetes mellitus
3)	creatinine clearance &lt; 35 ml/min
4)	pre-existing hypocalcemia must be treated by adequate intake of calcium and vitamin D before therapy with zoledronic acid
5)	active history of uveitis, iritis, or episcleritis 
6)	metastatic cancer or cancer diagnosed less than 2 years ago where treatment is still ongoing
7)	Active primary hyperparathyroidism
8)	Hypothyroidism, not appropriately controlled with long-term thyroxine therapy
9)	Serum 25-hydroxyvitamin D concentrations &lt;15 ng/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be contacted by our fracture care coordinator. After signing the consent form, the participant will be randomised into either the treatment or the placebo group.
Medication will be prepared by a doctor not involved with study participants. The medication will be then administered by a study nurse who is unaware of the contents. Thus all study personnel with patient contact will be blinded.</concealment>
    <sequence>Computer-generated random numbers in variable blocks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/02/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>SWAHS - Clinical Governance Office</primarysponsorname>
    <primarysponsoraddress>SWAHS Research Governance Officer
Research Office
Westmead Hospital
cnr Hawkesbury Rd  Darcy St
Westmead, NSW 2145</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceuticals</fundingname>
      <fundingaddress>Novartis Pharmaceuticals Australia Pty Ltd
54, Waterloo Road
North Ryde, NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Sydney</sponsorname>
      <sponsoraddress>THE UNIVERSITY OF SYDNEY
Level 6, Jane Foss Russell Building G02
The University of Sydney, NSW, 2006</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Christian Langton</othercollaboratorname>
      <othercollaboratoraddress>Room M207
Gardens Point campus
Queensland University of Technology
2 George Street, GPO Box 2434
Brisbane, QLD 4001</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a one year study to identify the effect of Zoledronate on marrow fat in patients who have suffered a minimal trauma fracture. Changes in marrow fat in femur and vertebrae will be quantified using CT and MRI images analised using an image analysis software (Tomovision).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SWAHS-Nepean</ethicname>
      <ethicaddress>Ethics Research Office
Nepean Hospital
Penrith, 2750, NSW</ethicaddress>
      <ethicapprovaldate>12/08/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>12/11/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Gustavo Duque</name>
      <address>Aging Bone Research Program
Discipline of Geriatric Medicine
Sydney Medical School - Nepean
University of Sydney
Level 5 South Block
Nepean Hospital
PO Box 63, Penrith,NSW, 2750</address>
      <phone>+61 2 47344278</phone>
      <fax>+61 2 47341817</fax>
      <email>gustavo.duque@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Mrs. Griselda Loza-Diaz</name>
      <address>Aging Bone Research Program
Discipline of Geriatric Medicine
Sydney Medical School - Nepean
University of Sydney
Level 5 South Block
Nepean Hospital
PO Box 63, Penrith, NSW, 2750</address>
      <phone>+61 2 47343357</phone>
      <fax />
      <email>emma.thembani@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mrs. Griselda Loza-Diaz</name>
      <address>Aging Bone Research Program
Discipline of Geriatric Medicine
Sydney Medical School - Nepean
University of Sydney
Level 5 South Block
Nepean Hospital
PO Box 63, Penrith,NSW, 2750</address>
      <phone>+61247341772</phone>
      <fax />
      <email>griselda.loza-diaz@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Gustavo Duque</name>
      <address>Level 5, South Block, Nepean Hospital
Penrith, NSW 2750</address>
      <phone>+61247344278</phone>
      <fax />
      <email>gustavo.duque@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>